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1Blood pressure (BP) displays daily variation in healthy peo-ple, peaking midmorning and falling during night-time 
sleep.1 Loss or attenuation of the nocturnal BP dip (referred 
to as nondipping) incurs significant health risk by promoting 
cardiac, renal, and vascular injury.2 Nondipping is an early 
characteristic of diabetes mellitus preceding and predicting the 
development of microalbuminuria.3 In patients with chronic 
kidney disease, nocturnal hypertension is associated with a 
faster rate of decline in renal function.4,5 Even if clinic or mean 
24-hour ambulatory BP is normal, loss of dipping significantly 
increases the risk of dialysis or incident cardiovascular mortal-
ity.6,7 Lowering sleep BP alone reduces risk of cardiovascular 
disease,8 suggesting that restoration of normal day:night BP 
variation is an important therapeutic goal.
Clinical studies show that the day:night variation in BP is 
strongly correlated with renal sodium excretion.9 The kidney is 
an important long-term regulator of BP and impaired pressure 
natriuresis may contribute to nocturnal hypertension10: BP 
remains elevated during sleep to facilitate sodium excretion 
and maintain 24-hour sodium balance.11,12 Certainly, hyper-
tensive and prehypertensive patients have a blunted day:night 
pattern of sodium excretion and excrete a greater fraction of 
their daily output at night.13 Moreover, dietary sodium restric-
tion can restore a dipping BP profile in salt-sensitive hyperten-
sive patients,14 presumably by reducing sodium load below the 
day-time excretory threshold. Mechanistically, hydrochloro-
thiazide, either alone15 or in combination with amlodipine16 or 
valsartan,17 reduces night-time BP and restores dipping BP in 
nondipping hypertensive patients. This suggests that inappro-
priate activation of the thiazide-sensitive NaCl cotransporter 
(NCC) is a strong determinant of nocturnal BP.
NCC activity is modulated by multiple hormonal sys-
tems acting through a regulatory cascade of serine/threonine 
kinases, including WNKs, SPAK, and OSR1.18 These control 
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phosphorylation at conserved residues in the N terminus, and 
thereby influence NCC activity and trafficking into the api-
cal membrane.18 The distal tubule also expresses the canoni-
cal circadian transcription factors per1/2, bmal1, clock, and 
cry1/2,19 and a recent cell-line study demonstrated tran-
scriptional regulation of NCC and WNK kinases by per1.20 
It is increasingly evident that circadian transcription factors 
influence renal function.21 Glucocorticoids play an impor-
tant role in the entrainment of renal clocks to the day:night 
cycle.22 In the aldosterone-sensitive distal nephron, glucocor-
ticoid actions are normally limited because of metabolism 
by 11β-hydroxysteroid dehydrogenase type 2 (11βHSD2).23 
However, modest glucocorticoid excess promotes sodium 
retention by activating transport in the aldosterone-sensitive 
distal nephron.24 Such perturbations, whether iatrogenic25 
or because of conditions such as Cushing syndrome,26 also 
impair BP rhythmicity and induce a nondipping BP profile.
Because 11βHSD2 is only expressed in some cells of the 
distal convoluted tubule (DCT), we hypothesized that gluco-
corticoids set the day:night variation of NCC activity. Using 
the complementary approaches of adrenalectomy and chronic 
corticosterone infusion, we found that flattening the day:night 
variation in hypothalamic–pituitary–adrenal axis activity also 
flattened the variation in NCC activity, inducing a nondipping 
BP, which could be restored by thiazide therapy.
Methods
Detailed Methods are available in the online-only Data Supplement.
Animals
C57BL6J/Ola mice (Harlan, United Kingdom) were used between 2 
and 4 months of age. Mice were acclimatized to a 12-hour light:dark 
cycle for at least 2 weeks before experiments and given free access to 
water and standard chow (maintenance diet 1; Special Diet Services, 
Essex, United Kingdom). The lights were turned on at 7:00 AM 
local time, and this was defined as Zeitgeber time 0 (ZT0); lights 
were turned off at 7 PM (ZT12). Experiments were performed under 
license from the UK Home Office and after approval by the University 
veterinary services.
Kidney Collection
Mice were culled by cervical dislocation <1-minute after removal 
from the holding room. Culls were performed at both 1:00 PM (ZT6) 
and 1:00 AM (ZT18) local time. The kidneys were rapidly excised 
and decapsulated, snap-frozen on dry ice and stored at −80°C.
Bilateral Adrenalectomy
This was performed under isoflurane anesthesia and buprenorphine 
(Vetergesic 0.1 mg/kg sc) analgesia. After recovery, adrenalecto-
mized and control mice were individually housed and given ad libi-
tum access to 0.9% saline and tap water.
Chronic Corticosterone Infusion
Elastomer pellets were used to encapsulate corticosterone for slow 
release. In vitro, the release rate was ≈3.7 mg/kg per day, and this 
was maintained during a 4-week period. Pellets were implanted sub-
cutaneously under isoflurane anesthesia and buprenorphine analgesia 
(Vetergesic 0.1 mg/kg sc).
Plasma Corticosterone Measurements
Approximately 20-μL blood was sampled from conscious mice via the 
tail vein at local time 7:00 AM and 7:00 PM, unless otherwise stated. 
Plasma was stored at −80°C before measurement of corticosterone 
concentration by commercial EIA (Enzo Life Sciences, Exeter, 
United Kingdom).
Daily Variation in Renal Excretion
Control mice were single housed in metabolic cages, and after 5 
days of acclimatization, food intake, water intake, urine output, and 
body weight were measured at 12-hour intervals. The concentration 
of sodium in urine was measured by flame photometry and used to 
calculate excretion rate in μmol/h. Urine concentration of both aldo-
sterone and corticosterone was measured by ELISA.27
Measurement of NCC in Urinary Exosomes
The number of exosomes in urine samples was measured by 
Nanoparticle Tracking Analysis (NanoSight Ltd, Amesbury, United 
Kingdom), as described.28
Immunoblotting
Western blots were performed on homogenized whole-kidney 
samples as we have described,29 using primary antibodies against 
NCC, pThr53-NCC, anti-pThr58-NCC, anti-pSer71-NCC, and anti-
NKCC2. Images were developed by electrochemiluminescence and 
quantified by densitometry using ImageJ, as described.30 The cross-
reactivity of NCC phospho-antibodies was determined by immuno-
precipitation experiments. Anti-pThr53-NCC and anti-pSer71-NCC 
were selective for NCC but anti-pThr58-NCC showed significant 
cross-reactivity with NKCC2 (Figure S1).
Quantitative Polymerase Chain Reaction
RNA was extracted from whole kidney and used for quantitative 
polymerase chain reactions with the Roche Universal ProbeLibrary 
(Data Supplement; Table). TBP, HPRT, and 18S rRNAs were used as 
endogenous control genes.
Immunofluorescence
Kidneys were fixed by aortic perfusion of 4% paraformaldehyde 
and then embedded in paraffin, sectioned at 5 μm and mounted onto 
glass slides. Sections were double-immunostained to colocalize NCC 
expression with glucocorticoid receptor, mineralocorticoid receptor 
(MR), or 11βHSD2.
BP Measurement
Radiotelemetry devices were inserted into male C57BL/6 mice under 
isoflurane anesthesia. Data were collected during a 1-minute period 
every 30 minutes at an acquisition rate of 1 kHz. Basal measurements 
were obtained >7 days before corticosterone (n=5) or blank (n=6) 
elastomer pellets were implanted subcutaneously. After 11 days, 
hydrochlorothiazide (80 mg/kg per day) was administered in drinking 
water. Hydrochlorothiazide concentration in plasma samples taken on 
the final experimental day was measured by liquid chromatography–
mass spectrometry.
Statistical Analysis
Data are presented as mean±95% confidence interval. The number 
of biological replicates (n) for each experimental group is given in 
the figure legends along with the test used for statistical analysis. 
The arithmetic mean BP was calculated for periods of subjective day, 
when mice were asleep, and subjective night, when mice were awake. 
Cosinor analysis was also used to calculate mesor (rhythm-adjusted 
mean) as the central tendency, period, amplitude, and acrophase. 
Data were smoothed using a moving average during 5 hours. For 
each experimental phase (baseline, corticosterone, and thiazide), the 
smoothed data for each individual mouse was collected in bins of 5 
consecutive days and fitted by the least squares methods to a cosinor 
curve using software available at www.circadian.org, as described.31 
Robustness/prominence of the rhythm was calculated as the percent-
age of the variance accounted for by the cosinor model. Statistical 
significance of the goodness of fit was P<0.000001 for each analysis 
and was corrected for multiple tests.
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Results
Basal Day:Night Variation in NCC Phosphorylation
Under basal conditions, BP and heart rate had a robust 24-hour 
rhythm, dipping during subjective day when mice were in the 
inactive phase (Figure S2). Urinary excretion of Na and K also 
had this variation, as did the urinary excretion of aldosterone 
and corticosterone (Figure S3).
Cosinor analysis identified peak systolic blood pressure 
(SBP) at ≈ZT 18 hours, (Table S2) with the nadir at ≈ ZT 6 
hours. We therefore assessed the renal mRNA expression of 
genes associated with circadian control, corticosteroid action, 
and within the NCC regulatory cascade at these 2 time points 
(Figure 1A). Of the circadian genes, per2, cry 1, and bmal1 
had a higher expression when animals were active; but there 
was no difference in expression of per1 or cry2 at these time 
points. The expression of the glucocorticoid-response genes, 
sgk1 and tsc22d3 (glucocorticoid-induced leucine zipper 
protein), was higher when mice were active than during the 
inactive phase. We found no day:night variation for the genes 
encoding the MR, the glucocorticoid receptor, or 11βHSD2. 
Co-localization of MR and glucocorticoid receptor with NCC 
was confirmed (Figure S4), but 11βHSD2 was only expressed 
in a small number of distal-DCT cells (Figure S5)
We found no day:night variation in slc12a3 (encodes 
NCC) expression or in any other transcripts within the NCC 
regulatory cascade at these 2 time points. The transcriptional 
changes detected here are largely consistent with those pub-
lished in the CIRCA database.32 We found no day:night varia-
tion for per1, cry2, and wnk1 expression. These genes do have 
a circadian transcriptional profile,32 but our time points of ZT6 
and ZT18 correspond to midway point between the peak and 
nadir of expression.
At the protein level, total NCC abundance had no day:night 
variation (Figure 1B), whereas the abundance of NCC phos-
phorylated on Thr53 (henceforth pNCC) was higher during 
the active phase in both male (Figure 1C) and female mice 
(Figure S6). The phosphorylation of NCC on Ser71 had no 
day:night variation (Figure S7).
Phosphorylation of Thr53 increases the half-life of NCC 
in the apical membrane33 and closely correlates to transporter 
activity.34 We measured the excretion of NCC in urinary 
exosomes as a noninvasive surrogate of transporter abundance 
in the DCT apical membrane. As for pNCC abundance, exo-
somal NCC excretion had a marked day:night variation and 
was higher during the active phase (Figure 1D).
Adrenalectomy Reduces NCC Expression and 
Blunts Day:Night pNCC Variation
Adrenalectomy significantly reduced circulating corticos-
terone levels and abolished day:night variation (Figure 2A). 
Although slc12a3 mRNA levels were not changed by adrenal-
ectomy (Figure S8), total NCC protein was reduced by ≈50% 
(Figure 2B). There was no significant day:night variation in 
pNCC levels in adrenalectomized mice (Figure 2C), and the 
variation in tsc22d3 expression was blunted (Figure S8). The 
day:night variation in the circadian genes per2, cry1, and 
bmal1 was maintained after adrenalectomy (Figure S8).
Clamping Plasma Corticosterone Abolishes Daily 
pNCC Variation
Next, we implanted slow-release corticosterone pellets, which 
eliminated the day:night variation and clamped corticosterone 
in the midphysiological range at ≈200 nmol/L (Figure 3A). 
The day:night variation in aldosterone levels was not affected 
by this maneuver (Figure 3B). Slc12a3 mRNA (Figure S9) 
and total NCC abundance (Figure 3C; Figure S10) were not 
changed by chronic corticosterone infusion but pNCC varia-
tion was abolished (Figure 3D; Figure S10). This reflected 
increased pNCC levels during the inactive phase in corticos-
terone-treated mice. Glucocorticoid clamping also increased 
expression of tsc2233 and sgk1 during the inactive period, as 
well as levels of cry1, bmal1 and per1 (Figure S9). A small 
but significant reduction in active phase urinary sodium excre-
tion was recorded in corticosterone-treated mice (Figure 3E), 
which was not attributable to reduced food intake (Figure 3F). 
Sodium excretion during the inactive phase was not different 
from controls.
Clamping Plasma Corticosterone Induces a 
Nondipping BP Profile
SBP (Figure 4A) and diastolic blood pressure (DBP; 
Figure 4B) were measured in mice by radiotelemetry before 
and after implantation of slow-release corticosterone (n=5) 
Table.  Cosinor Analysis of Systolic Blood Pressure in C57BL6 Mice Treated With Chronic Corticosterone or Vehicle Followed by 
Chronic Hydrochlorothiazide Treatment (80 mg/kg)
Baseline Pellet HCTZ
Variable Vehicle Corticosterone Vehicle Corticosterone Vehicle Corticosterone
Period, h 24 h 10 min±0 h 
16 min
24 h 12 min±0 h 
20 min
24 h 05 min±0 h 
13 min
23 h 12 min±4 h 
25 min
23 h 40 min±0 h 
34 min
24 h 18 min±0 h 
34 min
Acrophase (ZT) 16 h 59 min±0 h 
37 min
16 h 50 min±0 h 
53 min
16 h 56 min±0 h 
47 min
14 h 50 min±0 h 
53 min
17 h 16 min±1 h 
12 min
16 h 13 min±1 h 
29 min
Amplitude, mm Hg 9.9±2.6 9.3±2.9 8.4±1.9 4.4±3.2* 8.6±1.07 6.7±2.3 ‡
MESOR, mm Hg 123±3 123±6 123±2 130±5† 121±3 126±3
Robustness, % 72.5±11.2 76.2±7.4 73.1±9.4 39.6±28.0† 70.5±12.6 62.7±15.9
HCTZ indicates hydrochlorothiazide; and ZT, Zeitgeber time. Data are mean±95% confidence interval and were analyzed by matched 2-way ANOVA with Sidak post-
test made between baseline, pellet, and HCTZ. Values that are significantly different from baseline are italicized.
*P<0.0001; †P<0.001, ‡P<0.01.
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or control (n=6) pellets and then during thiazide therapy. 
Before implantation, daily rhythms of BP, heart rate, and 
locomotor activity were robust; acrophase, amplitude, and 
mesor were not different between groups (Table). Pellets 
were then implanted and, after recovery from anesthetic, 
the vehicle group immediately regained the daily rhythm of 
SBP (Figures 4A, 5A, and 5C) and DBP (Figures 4B and 
5D), which were not different from preimplant values. The 
corticosterone-treated group took longer to regain 24-hour 
periodicity and when they did, SBP was raised during sleep 
compared with baseline values in all mice (Figure 5A and 
5C). Corticosterone treatment increased DBP both in the 
active and in the inactive phases (Figure 5D). Changes to the 
day:night variation in SBP did not reflect changes in either 
locomotor activity or heart rate, as assessed by telemetry 
(Figure S11).
Cosinor analysis was performed on 5-day bins of steady-
state SBP (indicated by the blue boxes on Figure 4A). 
Corticosterone treatment significantly (P<0.001) increased 
mesor and significantly decreased both the amplitude and 
robustness (P<0.001) of the underlying rhythm (Table).
Chronic Thiazide Therapy Restores a Dipping BP 
Profile
In the next phase of the experiment, the mice were given 
hydrochlorothiazide in drinking water, achieving a plasma 
concentration of ≈15 μmol/L in both the groups. This did not 
alter BP in the control group but had a significant antihyper-
tensive effect in the corticosterone-treated mice (Figure 5B). 
Thiazide reduced SBP during the inactive phase without 
affecting SBP during the active phase (Figure 5C). A similar 
profile was observed for DBP, being reduced by hydrochlo-
rothiazide treatment when mice were asleep but remaining 
elevated during the active phase (Figure 5D). Cosinor analysis 
showed that hydrochlorothiazide restored a robust day:night 
rhythm for SBP in corticosterone-treated mice, reducing 
mesor and increasing amplitude to levels not significantly dif-
ferent from controls (Table).
Figure 1. Day:night variation of gene expression (A), total NaCl cotransporter (NCC) protein (B), phosphorylated NCC (pT53-NCC; C), 
and exosomal NCC (D) in C57BL6 mice. Kidneys were harvested at Zeitgeber time (ZT) 6 (day) and ZT18 (night) for immunoblots and 
quantitative polymerase chain reaction using whole kidney homogenate. A–C, Exosomal NCC was measured by Nano-tracking gated for 
20- to 100-nm particles labeled with Q-dot conjugated NCC antibody in 12-hour urine samples collected between ZT0–12 (day/sleep) 
and ZT12–0 (night/active). Two-way ANOVA with post hoc Sidak correction was carried out on gene expression data (n=15). Day:night 
total (n=6) and phosphorylated NCC (n=6) normalized densities in arbitrary units were compared by unpaired t tests. Exosomal NCC 
was corrected for urinary volume and analyzed by paired t tests. *P<0.0001, †P<0.001, ‡P<0.01, nonsignificant (ns) P>0.05. All data are 
mean±95% confidence interval.
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Discussion
We find that NCC has a day:night variation of activity 
determined by phosphorylation of existing protein rather 
than by gene transcription. This variation is influenced by 
the rhythm of circulating glucocorticoid. If this hormonal 
profile is flattened, NCC is inappropriately activated dur-
ing the inactive phase, inducing a nondipping BP profile. 
Hydrochlorothiazide, which inhibits NCC, reduced BP during 
the inactive phase only in corticosterone-treated mice, restor-
ing a robust day:night variation in BP.
Daily NCC Activity Is Determined by 
Phosphorylation
Around 4000 genes in the DCT exhibit day:night variation at 
the transcriptional level, of which ≈10% fit a circadian profile 
with a period of 24 hours.19 Genes found with circadian rhyth-
micity included clock transcription factors, such as per1/2, 
cry1/2, and bmal1.19,32 Glucocorticoid-induced genes, such as 
the kinase sgk1 and the transcriptional regulator tsc22d3, also 
displayed a circadian profile of transcription at whole-kidney 
level.32 Our data are consistent with this literature (day:night 
Figure 2. Day:night variation of plasma corticosterone (A and B), total NaCl cotransporter (NCC; C), and phosphorylated NCC (pNCC) 
protein (D) in adrenalectomized (ADX) and adrenal intact C57BL6 mice. A pooled profile of 24-hour plasma corticosterone was generated 
from composite terminal and spot plasma collections taken from ADX and control mice (A, n=8–20). Matched 2-way ANOVA was only 
performed on Zeitgeber time (ZT) 0 and ZT12 spot plasma samples collected concomitantly (B). The bar at the top of A and B indicates 
periods of light and dark. Kidneys were harvested at during the day when mice were asleep (ZT6) or at night when mice were awake (ZT18). 
Signal densities for immunoblots were normalized to Coomassie signal densities and compared with 2-way ANOVAs followed by post hoc 
Sidak correction. *P<0.0001, †P<0.001, ‡P<0.01, §P<0.05, nonsignificant (ns) P>0.05. All data are mean±95% confidence interval.
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transcriptional changes were found in per2, cry1, bmal1, 
sgk1, and tsc22d3); however, a limitation of our work is that 
it lacked the temporal resolution to detect rhythmic changes 
that have been reported for per1,19,32 cry2,19,32 mo25α,32 cul3,32 
and WNK132 expression. It is also important to note that we 
assessed transcription at the whole-kidney level and can-
not, therefore, discriminate between glucocorticoid-sensitive 
regions of the kidney and those with minimal glucocorti-
coid sensitivity (ie, the aldosterone-sensitive distal nephron) 
because of expression of 11βHSD2. In such regions sgk1 and 
tsc22d3 might be regulated by aldosterone.
Slc12a3, which encodes NCC, had no day:night rhythm of 
transcription,19,32 as we have confirmed here. Our data at the 
whole-kidney level underscore the concept that day:night vari-
ation in NCC activity is regulated by post-transcriptional mod-
ification of existing protein.19 Of the 3 important residues thus 
far defined, our data show day:night control of phosphoryla-
tion of Thr53, but not Ser71. We do not present data for Thr58 
phosphorylation, as we found significant cross-reactivity of 
this antibody with NKCC2, which is present in our samples.
pNCC abundance is often used as a surrogate marker for 
NCC activity as it correlates with thiazide-sensitive transport 
in cells34,32 and in the intact kidney.29 We chose not to assess 
thiazide-sensitive sodium transport directly because the req-
uisite approaches either increase corticosterone35 or abolish 
day:night rhythms of renal function.36 We instead used the 
excretion of NCC in urine exosomes to provide a noninvasive 
snap-shot of transporter abundance in the apical membrane 
of the DCT.37,38 Exosomal NCC excretion was higher when 
mice were active, as recently described in healthy humans.39 
In combination, these complementary experimental strategies 
indicate that thiazide-sensitive sodium transport is normally 
reduced during the inactive phase, correlating with the fall in 
BP and the lower ambient glucocorticoid level.
How Do Glucocorticoids Influence Daily Variation 
in NCC Activity?
The circadian rhythm of circulating glucocorticoids can entrain 
renal clock gene transcription.22 One hypothesis is that circa-
dian transcription factors are the link between circulating cor-
ticosterone and phosphorylation/activation of NCC. Per1 does 
regulate NCC activity, binding the promotor of slc12a3 and 
wnk4 to positively regulate transcription in a DCT cell line.20 
In our study, adrenalectomy abolished the daily variation of 
pNCC abundance but did not uniformly affect the variation in 
clock gene expression. A clearer relationship was observed in 
mice chronically infused with glucocorticoid. In this scenario, 
increased pNCC levels during the inactive phase were associ-
ated with increased transcription of per1, cry1, and bmal1. 
A clearer relationship to pNCC abundance across all experi-
mental paradigms was with sgk1 and tsc22d3 expression. An 
alternative hypothesis is that the circadian variation in gluco-
corticoids directly controls NCC activity by engaging a net-
work of regulatory kinases downstream of a corticosteroid 
Figure 3. Day:night variation of plasma corticosterone (A), urinary aldosterone (B), total NaCl cotransporter (NCC; C), phosphorylated 
NCC (pNCC) protein (D), urinary sodium (E), and food intake (F) in chronic corticosterone (Cort)- and vehicle-treated C57BL6 mice. 
Plasma was sampled in Cort- and vehicle-treated mice at Zeitgeber time (ZT) 0 and ZT12. Urinary aldosterone and sodium were 
measured in samples collected during the 12 hours of subjective day, when mice were asleep (ZT0–12) and over subjective night when 
mice were awake (ZT12–0). Food intake was measured during this time. These urine and food intake data are the average for each mouse 
during 2 consecutive days’ measurements. Kidneys were harvested at ZT6 (day/sleep) and ZT18 (night/active) for immunoblots using 
whole kidney homogenate. Plasma corticosterone, urinary aldosterone and sodium excretion, and food intake data were compared with 
matched 2-way ANOVA with post hoc Sidak correction. Normalized signal densities for immunoblots were analyzed using 2-way ANOVA 
with post hoc Sidak correction. *P<0.0001, †P<0.001, ‡P<0.01, §P<0.05, nonsignificant (ns) P>0.05. All data are mean±95% confidence 
interval.
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receptor and upstream of the WNK/SPAK/OSR1 kinase cas-
cade. Indeed, synthetic glucocorticoids increase the expres-
sion/activity of NCC,40,41 and recent studies show that sgk1 
enhances NCC activity indirectly by suppressing degradation of 
WNK1 kinase.42 Because we found that most DCT cells do not 
express 11βHSD2, corticosterone could induce sgk1 expression 
through either MR or glucocorticoid receptor activation43: MR 
is the most plausible route because MR antagonists abolish the 
endogenous rhythm of the WNK1/SPAK/OSR1 phosphoryla-
tion cascade.19 Nevertheless, an important limitation to our 
study is that gene expression and protein phosphorylation were 
assessed at only 2 time points. This lack of temporal resolution 
precludes cosinor analysis of these data sets and limits our abil-
ity to assess the relationship between glucocorticoid-activated 
transcriptional pathways and NCC activation.
How Do Glucocorticoids Induce a Nondipping BP 
Profile?
We chronically infused corticosterone such that plasma lev-
els were held midway between the physiological peak and 
trough. This rapidly induced nondipping BP, reflecting a sig-
nificant rise in BP during the inactive phase. Our approach 
models the loss of nocturnal BP observed in patients receiving 
chronic glucocorticoid therapy.25 Glucocorticoid insufficiency 
in humans and adrenalectomy in mice also achieve a flat daily 
cortisol/corticosterone profile. In this setting, the reduced 
day:night BP variation reflects a low-peak BP during waking 
hours.26,35 Overall, these data indicate that an intact glucocor-
ticoid rhythm is essential for the normal daily variation in BP: 
loss of this dynamic glucocorticoid control may contribute to 
increased cardiovascular mortality in patients on chronic glu-
cocorticoid therapy.36
What accounts for the loss of dip in our study? It is unlikely 
to reflect increased sympathetic drive in the inactive period,37 
since the daily variation in heart rate was not affected by corti-
costerone treatment. We also discount a major role for reduced 
arterial compliance38 because DBP increased (throughout the 
24-hour cycle), rather than fell, during corticosterone treatment. 
The most plausible explanation of our data are that corticoste-
rone activates the WNK/SPAK/OSR1 cascade and clamps NCC 
on throughout the 24-hour cycle. This impairs the normal modu-
lation of BP by pressure natriuresis, and in consequence BP does 
not fall during sleep to facilitate sodium excretion and maintain 
balance.39 Indeed, corticosterone infusion did not affect overall 
sodium balance but reduced sodium excretion during the active 
phase. This is consistent with data from normotensive humans: 
those excreting a greater proportion of the daily sodium load 
during sleep have a reduced dip during sleep.12 This concept is 
reinforced by data in adrenalectomized mice. These animals do 
not activate NCC during periods of activity and cannot main-
tain sodium balance by modulating renal excretion: BP lacks 
day:night variation because peak BP is significantly reduced.
Perspectives
Hydrochlorothiazide monotherapy was previously shown to 
reduce night-time BP in essential hypertensive patients, but 
only those with a nondipping BP profile.15 Night-time dos-
ing of hydrochlorothiazide (in combination with valsartan) 
Figure 4. Systolic blood pressure (SBP; A) and diastolic blood pressure (DBP; B) in C57BL6 mice after treatment with corticosterone or 
vehicle followed by chronic hydrochlorothiazide (HCTZ). Moving averages (during 5 hours) throughout the duration of the experiment are 
displayed here. After baseline recordings (11 days), all mice were anesthetized under isoflurane and received either vehicle or corticosterone 
slow-release silastic pellets (subcutaneously). After 11 days, all mice were treated with chronic HCTZ (80 mg/kg) in their drinking water. The 
blue rectangles indicate 5-day bins that were taken forward for further analysis. All data are mean±95% confidence interval (CI), n=6 (vehicle, 
black line) n=5 (corticosterone, red line), where thick lines are the mean, and thin-dotted lines are 95% CI.
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is more effective than daytime dosing at reducing BP dur-
ing sleep.17 Our study provides mechanistic insight into these 
outcomes and suggests that thiazides, or thiazide-like diuret-
ics with a longer half-life could improve BP control over the 
24-hour cycle in certain patients. Measuring urinary exo-
somal NCC in morning urine samples would be an effective 
and noninvasive means of patient stratification. We predict 
benefit in nondipping patients on glucocorticoid therapy or 
those with abnormal peripheral glucocorticoid metabolism. 
Restoring dipping BP profile through thiazide diuretics 
would be a cost-effective way of reducing cardiovascular risk 
in these patients.
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What Is New?
•	Persistent elevation of circulating glucocorticoids induced a nondipping 
blood pressure (BP) profile.
•	This nondipping BP was associated with persistent activation of the renal 
sodium chloride cotransporter.
•	Treatment with a thiazide diuretic reduced BP and restored the normal 
dipping rhythm.
What Is Relevant?
•	BP normally dips during sleep and loss of the nocturnal dip (nocturnal 
hypertension) increases the risk of cardiovascular and renal disease.
•	Elevated glucocorticoid levels may promote the nocturnal hypertension 
common in chronic stress, obesity, and type 2 diabetes mellitus.
•	 Long-lasting thiazide diuretics may improve BP control throughout the 
24-hour cycle.
Summary
This study suggests that thiazide diuretics may lower nocturnal 
blood pressure in conditions associated with abnormal glucocor-
ticoid metabolism, reducing long-term cardiovascular risk in such 
patients.
Novelty and Significance
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Supplementary Methods: 
 
Measurement of NCC in urinary exosomes: The number of exosomes in urine samples was 
measured by Nanoparticle Tracking Analysis (NTA, NanoSight Ltd, Amesbury, UK), as described
1
. 
NCC-containing exosomes were identified by fluorescence after conjugation of a rabbit anti-NCC 
antibody (AB3553; EMD Millipore) to a quantum dot (Qdot 605 Anti- body Conjugation Kit; 
Invitrogen, UK). For fluorescent NTA analysis, a 532nm (green) laser diode excited the Qdots with 
a long-pass filter (430nm) so that only fluorescent particles were tracked and labeled-particle 
concentration determined by NTA software. 
Immunoblotting: Western blots were performed as we have described
2
. Briefly, kidneys were 
homogenized in a sucrose buffer containing phosphatase, kinase, and protease inhibitors, and 
protein samples were resolved by SDS-PAGE (NuPAGE Novex 3%–8% Tris-acetate gels; 
Invitrogen, UK) and transferred to PDVF membrane (Amersham Hybond-P GE Healthcare). 
Primary antibodies used were: rabbit anti-NCC (AB3553; EMD Millipore, 1:1000); sheep anti-
pThr53-NCC, anti-pThr58-NCC, anti-pSer71-NCC (each at 1:500), and anti-NKCC2 (1:10,000, all 
from Division of Signal Transduction Therapy, Dundee University, UK). Secondary antibodies 
were: goat anti-rabbit IgG-HRP (sc-2030; Santa-Cruz Biotechnology, 1:2000), and donkey anti-
sheep IgG-HRP (A3415; Sigma-Aldrich, 1:20,000). Images were developed by 
electrochemiluminescence and quantified by densitometry using ImageJ. The bottom <50kDa of the 
gel was coomassie stained and used as a loading control, as described
3
. The cross-reactivity of NCC 
phospho-antibodies was determined by immunoprecipitation experiments. NCC and NKCC2 were 
separately pulled-down from whole kidney homogenates and the products probed using pThr53-
NCC, pThr58-NCC and pSer71-NCC antibodies. Anti-pThr53-NCC and anti-pSer71-NCC were 
selective for NCC but anti-pThr58-NCC showed significant cross-reactivity with NKCC2 (See 
Supplemental Material, Figure S1). 
Quantitative-PCR: RNA was extracted from frozen kidneys (RNeasy Mini Kit, Qiagen) and treated 
on-column with DNase I. cDNA was transcribed from 500 ng of total RNA and used for qPCR 
reactions with the Roche Universal ProbeLibrary (See Supplemental Material, Table 1). TBP, 
HPRT and 18S rRNAs were used as endogenous control genes. Their expression did not differ 
across any of the experimental groups. CT values were approximately 25-33, 22-28, 7-15 for TBP, 
HPRT and 18S, respectively. Test gene CT values ranged from 22 to 37. The level of endogenous 
control genes was normalized such that day/vehicle/sham was equal to 1. 
Immunofluorescence: Kidneys were fixed by aortic perfusion of 4% paraformaldehyde and then 
embedded in paraffin, sectioned at 5m and mounted onto glass slides.  Sections were double-
immunostained to co-localise NCC expression with GR, MR or 11HSD2; all sections were 
counterstained with DAPI (Immunodetection and Imaging Facility; The University of Edinburgh). 
Images were acquired using a Zeiss LSM 510 Meta Confocal Laser Scanning Microscope. DAPI, 
Cy3 and Cy5 were excited using a blue diode 405nm laser and HeNe 546nm and 633nm lasers 
respectively. Tiled images (~7x7) were captured through a 20X objective lens.  
BP measurement: Radiotelemetry devices (Model TA-11PAC-10, Data Systems International, UK) 
were inserted into male C57BL/6 mice under isoflurane anesthesia. After a week of post-operative 
recovery, data were collected over a 1-minute period every 30 minutes at an acquisition rate of 
1kHz. Basal measurements were obtained over 7 days before corticosterone (n=5) or blank (n=6) 
elastomer pellets were implanted subcutaneously. In order to verify that the plasma corticosterone 
clamping was sustained throughout the experiment, blood was sampled at ZT0 and ZT12 in vehicle 
and corticosterone treated mice on the last day of the telemetry experiment i.e. four weeks after 
implantation. After 11 days, hydrochlorothiazide (HCTZ; 80mg/kg/day) was administered in 
drinking water. The mice did not change their intake of water following HCTZ dosing. HCTZ 
concentration in plasma samples taken on the final experimental day was measured by LC/MS.  
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Table S1: Table of qRT-PCR assays. 
 
  
gene accession number forward primer reverse primer UPL 
Rn18s NR_003278.1 ctcaacacgggaaacctcac cgctccaccaactaagaacg 77 
Tbp NM_013684 gggagaatcatggaccagaa gatgggaattccaggagtca 97 
HPRT NM_013556.2 cctcctcagaccgcttttt aacctggttcatcatcgctaa 95 
per1 NM_001159367.1 gcttcgtggacttgacacct tgctttagatcggcagtggt 71 
per2 NM_011066 gcttcgtggacttgacacct tgctttagatcggcagtggt 5 
clock-201 NM_007715.5 ccagtcagttggtccatcatt tggctcctaactgagctgaaa 76 
cry1 NM_007771.3  ggcagagcagtaactgatacga tgactttcccaccaacttca 52 
cry2 NM_009963.4  ggagcatcagcaacacagg ccgcttggtcagttcttcac 11 
arnt1 var1 NM_001243048 gaatacattgtctcaaccaacactg ttagctgcgggaaggttg 97 
arnt1 var2 ENSMUST00000106637.1 agtacgcctccccctgat tgtctggagtccctccattt 79 
Sgk1 NM_001161845 gattgccagcaacacctatg ttgatttgttgagagggacttg 91 
TSC22d3 v2 NM_010286.3 tccgttaaactggataacagtgc tggttcttcacgaggtccat 49 
MR NM_001083906 caaaagagccgtggaagg tttctccgaatcttatcaataatgc 11 
GR NM_008173  tgacgtgtggaagctgtaaagt catttcttccagcacaaaggt 56 
Hsd11b2 NM_008289.2 cactcgaggggacgtattgt gcaggggtatggcatgtct 26 
Slc12a3 NM_019415 cctccatcaccaactcacct ccgcccacttgctgtagta 12 
Oxsr1 NM_133985 tgccttcaaaaggatccaga tggaaaaatttgtgcctcaac 84 
Stk39 ENSMUST00000102715 gtacgagctccaggaggttatc tcttgcctgggtttgcat 27 
Stk39 JN368425 ttaccgtcattcctaactttactgc gaatgcgcttactccaaaatct 18 
Wnk1 AY309076 cttttgccaagagtgtgataggt caacggattcatcatatttctcc 92 
Wnk1 AY311934 / AY309076 tgctgctgttctcaaaagga acttcaggaattgctactttgtca 20 
Wnk4 NM_175638 tccgatttgatctggatgg gggcaggatgaactcattgta 26 
Nedd4 NM_010890    acgtgctgttcactgctgat tcacaactcgtgtgtcatcg 1 
Cab39 NM_133781 tgagaaggagcctcagacaga aaaatttgagccacgtcttttt 17 
Cul3 NM_016716.4 agaagggaagaatcctgttgact gccggtcattattgaaggatt 69 
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Table S2: Parameters obtained from cosinor analysis of C57BL6 mice telemetry data. Data are 
mean± 95% CI. (n=4)  
Variable SBP DBP HR Activity 
Period (hours) 
23h09 
±0h22 
23h09 ±0h18  
23h48 ± 
0h12 
23.48 ±0h12  
Acrophase (ZT) 18h10±0h47 18h09±0h49 17h06±0h05 17h06±0h05  
Amplitude (mmHg/bpm/counts) 10.0 ± 1.8 9.8 ± 1.5 57.0 ± 22 6.24 ± 1.2 
MESOR (mmHg/bpm/counts)  125 ± 2 95 ± 5 507 ± 7 7± 2 
Robustness (%) 26.3±4.3 23.9±3.3 12.5±5.0 28.5±1.9 
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Immunoprecipitation (IP) for specificity of NCC phospho-antibodies:  
The NCC phospho-motifs are conserved in other related transporters, particularly NKCC2. 
Threonine 53 and 58 on NCC shares homology with Threonine 96 and 101 on NKCC2. Therefore 
IP was performed to test the specificity of the NCC phospho-antibodies. Superparamagnetic beads 
(Dynabeads
TM
 Protein G, Life Technologies) were washed and conjugated to NCC and NKCC2 
antibodies according to the manufacturer’s instructions. 2500mg kidney homogenate was added to 
the bead-antibody mixture and placed on a magnet to “pull-down” proteins bound to the antibodies. 
The antigens were eluted and resuspended (in 20L DynabeadsTM elution buffer, Life 
Technologies, 3L DTT and 7.5L LDS) and, along with a standard kidney homogenate, were 
Western blotted.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1: Cross-reactivity of anti-NCC antibodies 
Immunoprecipitation was used to “pull down” NCC or NKCC2 from 2500 g of total kidney 
homogenate. These immunoprecipitation products (+) were then separated on 3-8% Tris Acetate 
gel, transferred to Hybond P membrane and immunoblotted for the NCC phospho-antibodies and 
NKCC2. 12 g of total kidney homogenate (-) was run alongside the IP products and probed 
directly as a positive control. 
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Figure S2: 24-hour systolic blood pressure (A), diastolic blood pressure (B), heart rate (C) and 
activity (D) in C57BL6 mice. Data were collected using radiotelemetry and are shown as hourly 
mean over 5-day batches (thick line) ±95% CI (thin dotted line) (n=4). The white bar indicates 
subjective day, when mice were inactive; the black bar indicates the subjective night, when mice 
were active. Lights were turned on at 7am local time (ZT0). 
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Figure S3: Urinary aldosterone (A), corticosterone (B), sodium (C) and potassium (D) excretion 
and food intake (E). Urine samples were collected over subjective day (black circle; ZT0-12), when 
mice were inactive and over the night (red square; ZT12-0), when mice were active. These data are 
the average for each mouse over two consecutive days’ measurements. Data are mean ±95% CI. 
Statistical comparisons were made using paired Student’s t tests, ****P<0.0001 ***P<0.001. 
**P<0.01 (n=10). 
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Figure S4: Representative images of immunofluorescent staining of (A) NCC (green) and MR (red) 
and (B) NCC (green) and GR (red) in male C57BL6 mice. High-powered views of yellow-boxed 
regions are displayed. Bar, 100m in large top/bottom panels; 10m in high-powered middle 
panels. 
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Figure S5: Immunofluorescent staining for NCC (green) and 11HSD2 (red) in 3 (A-C) male 
C57BL6 mice. High-powered views of yellow-boxed regions are given on the right where blue 
arrows indicate regions in which 11HSD2 and NCC staining are within the same cell/tubule. Bar, 
100m (left-hand panels); 10m (right hand panels). 
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Figure S6: Day:night variation of NCC phosphorylation at Thr53 in female C57BL6 mice. Kidneys 
were harvested at ZT6 (day/inactive phase) and ZT18 (night/active phase) for immunoblots. No 
attempt was made to synchronize the oestrus cycles of these mice. Signal densities for immunoblots 
were normalised to Coomassie signal density and compared by unpaired t-tests, **P<0.01, All data 
are mean ± 95% CI.    
 
Figure S7: Day:night variation of NCC phosphorylation at Ser71 in male C57BL6 mice. Kidneys 
were harvested at ZT6 (day/inactive phase) and ZT18 (night/active phase) for immunoblots. Signal 
densities for immunoblots were normalised to Coomassie signal density and compared by unpaired 
t-tests. ns, P>0.05. All data are mean ± 95% CI 
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Figure S8: Gene expression in kidneys of adrenalectomised (ADX) and adrenal intact C57BL6 
mice. Control and ADX mice were single housed and culled at day 9 post surgery during the 
subjective day when inactive (black circle; ZT6) or night (red square; ZT18), when active. The 
encoding gene is given with name of the resulting protein in brackets. Gene expression of each gene 
was normalised to the average expression of 18S, TBP and HPRT. Data are mean ± 95% CI. Data 
were analysed with two-way ANOVA followed by post hoc Sidak correction, where ***P<0.001, 
**P<0.01 *P<0.05, ns P>0.05 (n=5-6). 
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Figure S9: Gene expression in kidneys of corticosterone (Cort) or vehicle treated C57BL6 
mice. Mice were culled during the subjective day when inactive (black circle; ZT6) or night (red 
square; ZT18), when active.  
The encoded protein name is given in brackets. Gene expression of each test gene was normalised 
to the average expression of 18S, TBP and HPRT. Data are mean ± 95% CI. Data were analysed 
with two-way ANOVA followed by post hoc Sidak correction, where ****P<0.0001, ***P<0.001, 
**P<0.01 *P<0.05, ns P>0.05 (n=9) 
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Figure S10: Immunoblots for pT53 NCC (A) pS71 NCC (B) and total NCC (C) in vehicle and 
corticosterone treated mice.  Mice were culled in groups of 3 control and 3 experimental animals 
during the subjective day when inactive (ZT6) or night (ZT18), when active. The experiment was 
performed on three separate occasions and immunoblots were performed in these batches (1-3). “R” 
is reference load, which was a pooled sample that was used to normalise across the three batches of 
immunoblots.  
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Figure S11: Heart rate and activity in C57BL6 mice.  After 11 days of baseline recording, mice 
received either corticosterone (red line) or control (black line) pellets. After a further 11 days, all 
mice received HCTZ (80 mg/kg) in their drinking water. Data displayed here are the moving 
average (over 5 hours) of heart rate (A) and activity (D) throughout the duration of the experiment. 
The blue rectangles indicate 5-day bins that were taken forward for further analysis. Summary mean 
daytime and nighttime heart rate (B, C) and activity (E, F) were obtained by taking the mean over 
the 5-day bins for subjective day, when mice were inactive (ZT3-8) and night (ZT15-20), when 
mice were active. Data are mean ± 95% CI, where thick lines are mean and feint lines are 95% CI. 
Summary data were analysed by matched two-way ANOVA with post hoc Sidak correction. 
****P<0.0001, ***P<0.001, **P<0.01, *P<0.05 ns, not significant P>0.05, n=6 (vehicle) n=5 
(corticosterone).  
 
1 3 6 8 11 16 21 23 26 28 31
400
500
600
700
Day
H
e
a
rt
 r
a
te
 (
b
p
m
)
Vehicle
Cort
Baseline
Chronic HCTZ
Cort/Vehicle Pellet
Baseline Pellet HCTZ
400
450
500
550
b
p
m
Day Time Mean
Vehicle
Cort*
Interaction ns
Treatment **
Group ns
Matching *
*
1 3 6 8 11 16 21 23 26 28 31
0
10
20
30
Day
A
c
ti
v
it
y
 (
c
o
u
n
ts
)
Vehicle
Cort
Baseline
Chronic HCTZ
Cort/Vehicle Pellet
Baseline Pellet HCTZ
0
2
4
6
8
c
o
u
n
ts
Day Time Mean
Vehicle
Cort
Interaction ns
Treatment ns
Group ns
Matching ****
Baseline Pellet HCTZ
450
525
600
675
b
p
m
Night Time Mean
Vehicle
Cort
*
Interaction ns
Treatment ***
Group ns
Matching ****
**
**
Baseline Pellet HCTZ
0
5
10
15
20
c
o
u
n
ts
Night Time Mean
Vehicle
Cort
Interaction ns
Treatment ns
Group ns
Matching ****
(A)
(B)
(E)
(C)
(D)
(F)
Heart Rate
Activity
